Skip to main content
Premium Trial:

Request an Annual Quote

Shifting Focus to Drug Development, Sialix Raises $2M, Changes Name to Siamab Therapeutics

Premium

NEW YORK (GenomeWeb) – Sialix said this week that it has raised an additional $2 million as part of its Series B round, bringing the total raised to $6 million.

The company also said that it has changed its name to Siamab Therapeutics, marking its shift from a glycomics-focused firm to one focused on developing therapeutic antibodies for cancer.

Siamab's glycomics technologies enable the firm to discover and assay antibodies to tumor associated carbohydrate antigens, a class of cancer-specific cell surface molecules suitable for targeting with antibody drugs. Using the platform the company has discovered and characterized a panel of anti-TACA antibodies that compose its first therapeutics development program.

"As we move forward with our focus on developing antibodies for the treatment of cancer, while staying true to our roots in glycobiology, we have chosen the name Siamab Therapeutics," CEO Jeff Behrens said in a statement. "Our technology platform has identified a panel of highly specific antibodies shown to significantly inhibit the growth of tumors in in vivo studies. Siamab’s lead program is currently in preclinical studies for the treatment of solid tumors."

The investors in the additional round of funding included Boston Harbor Angels, Mass Medic Angels, Launchpad Angels, Maine Angels, Beacon Angels and Desert Angels, as well as other undisclosed individuals.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.